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Abstract 
Vulvar cancer is a relatively rare disease. The aim of this study was to investigate prognostic factors in vulvar squamous 
cell carcinoma patients treated with primary surgery. Forty cases of vulvar squamous cell carcinoma treated with 
primary surgery were retrospectively analyzed. Overall survival (OS) and disease-specific survival (DSS) were calculated 
using the Kaplan–Meier method and prognostic factors were analyzed by multivariate analyses. The median age 
was 68 years. The FIGO stage distribution was as follows: 18 cases (45.0 %) in stage I, four cases (10.0 %) in stage II, 15 
cases (37.5 %) in stage III, and three cases (7.5 %) in stage IV. A radical local excision was performed in 15 patients, and 
radical vulvectomy in 25 patients, and seven of these patients were treated with postoperative RT. The 5-year DSS rate 
was 72.6 %, and the 5-year OS rate was 70.3 %. Age and surgical margin ≤5 mm were independent prognostic factors 
for OS, and positive inguinal LN metastasis and surgical margin ≤5 mm were identified as independent prognostic 
factors for DSS. Complete radical excision is important regardless of operation mode. Adjuvant treatment should be 
considered for inguinal LN positive patients.
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Background
Vulvar cancer is a relatively rare disease, represent-
ing only 3–5 % of gynecologic malignancies. It typically 
affects older women aged 65–70  years, although the 
incidence among younger women is increasing. Around 
90 % of vulvar cancers are squamous cell carcinomas. The 
standard treatment for early disease consists of radical 
local excision of the primary tumor with sentinel lymph 
node (LN) biopsy and/or inguinal lymphadenectomy. 
Advanced disease is often managed with a combination 
of radiation therapy (RT) and/or chemotherapy (Hacker 
2005; Beller et al. 2006; Joura 2002). However, the appro-
priate treatment in each case should be selected by tak-
ing into account the age of the patient, tumor location, 
performance status (PS), and various complications. 
To date, there are limited data on treatment modalities, 
patterns of failure, and prognostic factors in Japanese 
patients with vulvar cancer. In the present study, we ret-
rospectively reviewed the medical records for squamous 
cell carcinoma of the vulva cases treated with primary 
surgery in our department, and summarized prognostic 
factors and failure patterns.
Patients and methods
Forty cases of vulvar squamous cell carcionma treated 
with primary surgery at the University of the Ryukyus 
Hospital from 1984 to 2012 were retrospectively ana-
lyzed. Clinicopathological characteristics (age, histologic 
type, tumor diameter, tumor marker, LN metastasis, 
distant metastasis, type of treatment, adverse effects of 
treatment, and site of recurrence) were surveyed. The 
International Federation of Gynecology and Obstetrics 
(FIGO) 2009 staging classification (Hacker 2009) was 
used. Past cases classified with the FIGO 1988 stag-
ing classification were reclassified based on the 2009 
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classification. Overall survival (OS) and disease-specific 
survival (DSS) were calculated using the Kaplan–Meier 
method, and log-rank tests were used to determine the 
significance. Prognostic factors for OS and DSS were 
analyzed using the Cox proportional hazard model, and 
risk factors for local–regional and distant recurrences 
were examined using logistic regression analysis. A P 
value <0.05 was considered statistically significant. All 
statistical analyses were performed using JMP v10 (SAS 
Institute Inc., Cary, NC).
All patients provided written informed consent before 
treatment. This retrospective study was conducted 
according to the principles stated in the 1964 Declaration 
of Helsinki with subsequent revisions and was approved 
by the Institutional Review Board of our university (#662) 
in June, 2014.
Results
The median age was 68  years (range 37–90  years), and 
the median observation period was 62.5  months (range 
4–353 months). The FIGO stage distribution was as fol-
lows: 18 cases (45.0 %) in stage I, four cases (10.0 %) in 
stage II, 15 cases (37.5  %) in stage III, and three cases 
(7.5  %) in stage IV. The median tumor size was 33  mm 
(range 8–105  mm). A radical local excision was per-
formed in 15 patients, and radical vulvectomy in 25 
patients, and seven of these patients were treated with 
postoperative RT. With regards to inguinal LN dissec-
tion, it was omitted in patients with suspicious stage IA, 
and unilateral dissection or sampling of LNs was per-
formed in patients with small tumor in one side. During 
the follow-up period of 62.5 months, 19 patients showed 
no evidence of disease, and three were alive with disease. 
Seventeen patients (42.5  %) had recurrence, which was 
local–regional in three cases, distant in five cases, and 
both local–regional and distant in nine cases. Fourteen 
patients died of the vulvar cancer and four patients died 
of intercurrent disease (Table 1).
The 5-year DSS rate was 72.6 %, and the 5-year OS rate 
was 70.3 %. The 5-year DSS and OS by each variable are 
shown in Table 2. The 5-year DSS rates were 82.5 % for 
stage IB, 100 % for stage II, 55.2 % for stage III, and 33.3 % 
for stage IV. The 5-year OS rates were 75.0 % for stage IB 
disease, 100 % for stage II, 55.2 % for stage III, and 33.3 % 
for stage IV. There were significant differences in survival 
among the FIGO stages. Positive inguinal LN metastasis 
and surgical margin ≤5 mm were significant and tumor 
size ≥4 cm was marginal for both DSS (Figs. 1, 2) and OS. 
Age ≥70  years was significant for OS but not for DSS. 
The 5-year DSS rates were 74.8 % for radical vulvectomy, 
and 68.3 % for radical local excision (P = 0.774), and the 
5-year OS rates were 71.2 % for radical vulvectomy, and 
68.3  % for radical local excision (P =  0.521). Therefore, 
there were no significant differences in survival among 
operation procedures.
The prognostic factors for DSS and OS were analyzed 
using a Cox proportional hazard model. Age ≥70  years 
(P  =  0.040) and surgical margin ≤5  mm (P  =  0.028) 
were independent prognostic factors for OS, and positive 
inguinal LN metastasis and surgical margin ≤5 mm were 
identified as independent prognostic factors for DSS 
(Table  3). The predictive factors for local–regional and 
distant recurrence were analyzed using a logistic regres-
sion analysis. There was no significant predictive fac-
tor for local–regional and distant recurrences (data not 
shown).
Discussion
In this study, the FIGO 2009 staging classification 
(Hacker 2009) was used, and cases prior to 2009 were 
reclassified based on this classification. The performance 
of the revised staging system had been assessed in a 
Table 1 Patient characteristics (N = 40)
a The International Federation of Obstetrics and Gynecology
b Radiation therapy
c No evidence of disease
d Alive with disease
e Died of disease
f Died of intercurrent disease
Variables









Tumor size (mm) (range) 33 (8–105)
Surgery
 Radical local excision 15
 Radical vulvectomy 18
 Radical vulvectomy + RTb 7
Recurrence sites
 Local–regional 3







Follow up period (months) 62.5 (4–353)
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number of studies; however, the results are conflicting 
(van der Steen et al. 2010; Tabbaa et al. 2012). Looking at 
OS and DSS based on the FIGO stage, the classification 
gave a good spread of prognostic groupings. Tumor size 
was not an independent prognostic factor. Inguinal LN 
metastasis, and the number, size, and morphology of the 
Table 2 Univariate analysis for disease-free survival and overall survival
a Lymph node
b Radical local excision
c Radical vulvectomy
d Died of disease
e Disease-specific survival
f Overall survival
Variables n No. of DODd 5y-DSSe (%) p value No. of death 5y-OSf (%) p value
Age (years)
 70≤ 23 7 51.0 0.146 11 46.4 0.0049
 70≥ 17 7 82.6 7 82.6
Stage (FIGO 2009)
 Ia 6 0 100 0.0028 0 100.0 0.0093
 Ib 17 2 82.5 5 75.0
 II 5 2 100 2 100.0
 III 16 7 55.2 8 55.2
 IV 4 3 33.3 3 33.3
Tumor size
 4 cm≤ 17 8 59.9 0.0577 9 54.9 0.0791
 4 cm> 23 6 81.5 9 81.5
Inguinal LNa metastasis
 Negative 22 4 89.8 0.0059 7 85.4 0.0161
 Positive 18 10 51.9 11 51.9
Surgical resection margin
 >5 mm 34 10 76.9 0.0243 13 74.1 0.0066
 ≤5 mm 6 4 50.0 5 50.0
Operation mode
 RLEb 15 5 68.3 0.774 7 68.3 0.521
 RVc 25 9 74.8 11 71.2
Fig. 1 The 5-year disease-specific survival rate was 89.8 % in patients 
with positive inguinal lymph node and 51.9 % in patients with nega-
tive inguinal lymph node
Fig. 2 The 5-year disease-specific survival rate was 76.9 % in patients 
with surgical margin >5 mm and 50.0 % in patients with surgical 
margin ≤5 mm
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positive nodes are taken into account in the classification. 
LN metastasis is a good prognostic marker that provides 
a clear distribution across tumor stages, although we 
could not apply it to stages IIIA, IIIB, and IIIC because 
of the small number of patients in the present study. The 
FIGO 2009 staging classification seems to allow better 
prognostic discrimination between stages and less het-
erogeneity within stages than the earlier version.
In most cases, radical vulvectomy with inguinofemoral 
lymphadenectomy should be considered as an appropri-
ate treatment for vulvar cancer in the 70s and early 80s. 
However, to reduce surgical morbidity, radical local exci-
sion of the primary tumor has generally replaced radi-
cal vulvectomy. Previous studies reported no significant 
difference in prognosis for this approach, even when 
compared with extensive surgery (De Hullu et  al. 2002; 
Stehman et al. 1992). Also, in our patients, no significant 
difference in prognosis was observed among the opera-
tive procedures. Radical local excision of the primary 
tumor has generally instead of radical vulvectomy is 
appropriate to reduce surgical morbidity.
In the multivariate analysis in the present study, age 
≥70 years and close surgical resection margin were inde-
pendent prognostic factors for OS, but not for DSS. In 
our study population, the fact that four patients died of 
intercurrent disease and all patients were aged ≥70 years. 
Furthermore, under treatment of elderly patients was 
observed, such as postoperative radiotherapy was omit-
ted in six of 8 patients with positive groin nodes and 
two of three patients with close surgical margin. These 
points may have affected OS. A surgical resection margin 
<8  mm has been reported to be associated with a high 
recurrence rate (Heaps et  al. 1990). Cases with a surgi-
cal margin ≤5 mm have a high local recurrence rate, but 
radiation with a dose ≥56  Gy may decrease the risk of 
vulvar recurrence (Viswanathan et  al. 2013). Therefore, 
pathologic margin distance is an important predictor of 
local vulvar recurrence. Chan et al. (2007) suggested that 
a ≥8 mm pathologic margin clearance leads to a high rate 
of local–regional control. Our data were consistent with 
the findings of the previous studies.
In our study, 18 patients had positive inguinal LNs. 
Seven of these patients underwent postoperative RT, 
whereas 11 were treated with surgical resection only. Of 
those 18 patients, 11 had recurrence, including 3 of the 7 
patients who underwent postoperative RT, and eight of 
the 11 patients were treated with surgical resection only. 
The patients who received no radiation included higher 
age (n  =  6), stage IIIA (n  =  3) and unknown (n  =  2). 
Only local–regional recurrence was observed in one case, 
only distant recurrence in four, and both local–regional 
and distant recurrences in six cases. An increased risk of 
recurrence has been described in patients with LN metas-
tases, large primary tumors, deep invasion, lymphovas-
cular invasion and close surgical margins (Heaps et  al. 
1990; Binder et al. 1990; Burger et al. 1995; Woelber et al. 
2009). RT is playing an increasing role in the manage-
ment of patients with carcinoma of the vulva, in combi-
nation with radical local excision. Post radical vulvectomy 
RT in locally advanced tumors improves tumor control at 
the primary site and in the regional lymphatics compared 
with surgery alone (Perez et al. 1998). RT alone or in com-
bination with LN dissection is highly effective in prevent-
ing inguinal node recurrence in patients with squamous 
cell carcinoma of the vulva (Katz et  al. 2003). Adjuvant 
groin and pelvic RT is the standard of care for node-posi-
tive vulvar squamous cell carcinoma for patients with two 
or more involved LNs, extracapsular extension, or inad-
equate LN dissection based on Gynecologic Oncology 
Group (GOG) 37 (Homesley et al. 1986). Because of a lim-
ited number of patients with only one LN involved, ade-
quate power was not reached to determine the benefit of 
RT (Kunos et al. 2009). A Surveillance, Epidemiology, and 
End Result (SEER) analysis indicated that for single ingui-
nal LN involvement, adjuvant RT improved disease-spe-
cific survival and increased OS if <12 LNs were removed 







HRc 95 % CId P value HRc 95 % CId P value
Age ≥70 years 1.414 0.427–4.544 0.560 2.891 1.051–8.366 0.040
Tumor size ≥4 cm 1.417 0.4334–4.957 0.566 1.495 0.490–4.732 0.481
Inguinal LNe metastasis 4.459 1.189–19.06 0.0264 2.639 0.825–8.570 0.101
Surgical margin ≤5 mm 4.640 1.128–17.57 0.0348 4.053 1.177–12.94 0.028
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(Parthasarathy et  al. 2006). However, not all studies of 
adjuvant radiation have supported these results (Groenen 
et al. 2010; Fons et al. 2009).
While the addition of concurrent chemotherapy to RT 
has increased over the past decade for advanced vulvar 
cancers (Han et al. 2000; Moore et al. 2012), the impact 
in the adjuvant setting is currently unknown. Recently, 
a population-based analysis using the National Cancer 
Data Base (NCDB) showed that adjuvant chemotherapy 
resulted in a significant reduction in mortality risk for 
node-positive vulvar cancer patients who received adju-
vant RT, reinforcing the use of adjuvant chemotherapy 
to improve outcomes in this high-risk subset (Gill et  al. 
2015). Because our patients had high frequency of distant 
failure, we may consider adjuvant chemotherapy concur-
rent with RT.
Strength of our study is past cases classified with the 
FIGO 1988 staging classification were reclassified based 
on the 2009 classification. We have shown a good prog-
nostic distribution of FIGO 2009 classification. Weak-
ness is this analysis is retrospective in a small number of 
patients from one center over a relatively long period of 
time.
In conclusion, we retrospectively analyzed 40 patients 
with squamous cell carcinoma of the vulva treated with 
primary surgery. The important prognostic factors were 
inguinal LN metastasis and close surgical resection mar-
gin. Complete radical excision is important regardless of 
operation mode. Adjuvant treatment should be consid-
ered for inguinal LN positive patients.
Authors’ contributions
The work presented here was carried out in collaboration among all authors. 
SI, MI, WK, and YA designed methods, analyzed the data, interpreted the 
results, and wrote the manuscript. All authors treated patients. All authors read 
and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 9 July 2015   Accepted: 12 February 2016
References
Beller U, Quinn MA, Benedet JL et al (2006) Carcinoma of the vulva: FIGO 26th 
annual report on the results of treatment in gynecological cancer. Int J 
Gynaecol Obstet 95(Suppl 1):S7–S27
Binder SW, Huang I, Fu YS et al (1990) Risk factors for the development of 
lymph node metastasis in vulvar squamous cell carcinoma. Gynecol 
Oncol 37:9–16
Burger MP, Hollema H, Emanuels AG et al (1995) The importance of the groin 
node status for the survival of T1 and T2 vulvar carcinoma patients. 
Gynecol Oncol 57:327–334
Chan JK, Sugiyama V, Pham H et al (2007) Margin distance and other clinico-
pathologic prognostic factors in vulvar carcinoma: a multivariate analysis. 
Gynecol Oncol 104:636–641
De Hullu JA, Hollema H, Lolkema S et al (2002) Vulvar carcinoma. The price of 
less radical surgery. Cancer 95:2331–2338
Fons G, Groenen SM, Oonk MH et al (2009) Adjuvant radiotherapy in patients 
with vulvar cancer and one intra capsular lymph node metastasis is not 
beneficial. Gynecol Oncol 114:343–345
Gill BS, Bernard ME, Lin JF et al (2015) Impact of adjuvant chemotherapy with 
radiation for node-positive vulvar cancer: a National Cancer Data Base 
(NCDB) analysis. Gynecol Oncol 137:365–372
Groenen SM, Timmers PJ, Burger CW (2010) Recurrence rate in vulvar carci-
noma in relation to pathological margin distance. Int J Gynecol Cancer 
20:869–873
Hacker NF (2005) Vulvar cancer. In: Berek JS, Hacker NF (eds) Practical gyneco-
logic oncology, 4th edn. Williams & Wilkins, Philadelphia, pp 585–602
Hacker NF (2009) Revised FIGO staging for carcinoma of the vulva. Int J 
Gynecol Obstet 105:105–106
Han SC, Kim DH, Higgins SA et al (2000) Chemoradiation as primary or adju-
vant treatment for locally advanced carcinoma of the vulva. Int J Radiat 
Oncol Biol Phys 47:1235–1244
Heaps JM, Fu YS, Montz FJ et al (1990) Surgical-pathologic variables predictive 
of local recurrence in squamous cell carcinoma of the vulva. Gynecol 
Oncol 38:309–314
Homesley HD, Bundy BN, Sedlis A et al (1986) Radiation therapy versus pelvic 
node resection for carcinoma of the vulva with positive groin nodes. 
Obstet Gynecol 68:733–740
Joura EA (2002) Epidemiology, diagnosis and treatment of vulvar intraepithe-
lial neoplasia. Curr Opin Obstet Gynecol 14:39–43
Katz A, Eifel PJ, Jhingran A et al (2003) The role of radiation therapy in prevent-
ing regional recurrences of invasive squamous cell carcinoma of the 
vulva. Int J Radiat Oncol Biol Phys 57:409–418
Kunos C, Simpkins F, Gibbons H et al (2009) Radiation therapy compared with 
pelvic node resection for node-positive vulvar cancer: a randomized 
controlled trial. Obstet Gynecol 114:537–546
Moore DH, Ali S, Koh WJ et al (2012) A phase II trial of radiation therapy and 
weekly cisplatin chemotherapy for the treatment of locally-advanced 
squamous cell carcinoma of the vulva: a gynecologic oncology group 
study. Gynecol Oncol 124:529–533
Parthasarathy A, Cheung MK, Osann K et al (2006) The benefit of adjuvant 
radiation therapy in single-node-positive squamous cell vulvar carci-
noma. Gynecol Oncol 103:1095–1099
Perez CA, Grigsby PW, Chao C et al (1998) Irradiation in carcinoma of the vulva: 
factors affecting outcome. Int J Radiat Oncol Biol Phys 42:335–344
Stehman FB, Bundy BN, Dvoretsky PM et al (1992) Early stage I carcinoma 
of the vulva treated with ipsilateral superficial inguinal lymphadenec-
tomy and modified radical hemivulvectomy: a prospective study of the 
Gynecologic Oncology Group. Obstet Gynecol 79:490–497
Tabbaa ZM, Gonzalez J, Sznurkowski JJ et al (2012) Impact of the new FIGO 
2009 staging classification for vulvar cancer on prognosis and stage 
distribution. Gynecol Oncol 127:147–152
van der Steen S, de Nieuwenhof HP, Massuger L et al (2010) New FIGO staging 
system of vulvar cancer indeed provides a better reflection of prognosis. 
Gynecol Oncol 19:520–525
Viswanathan AN, Pinto AP, Schultz D et al (2013) Relationship of margin status 
and radiation dose to recurrence in post-operative vulvar carcinoma. 
Gynecol Oncol 130:545–549
Woelber L, Mahner S, Voelker K et al (2009) Clinicopathological prognostic 
factors and patterns of recurrence in vulvar cancer. Anticancer Res 
29:545–552
